Efficacy of Fluconazole Prophylaxis for Autologous Peripheral Blood Stem Cell Transplantation: Results of a Prospective, Randomized, Controlled, Multicenter, Open Label Study.

Tracey L. Walsh, Carlos Bachier, Paul Shaughnessy, Cesar O. Freytes, Natalie Callander, C. Fred LeMaistre, Michael Grimley, Patrick Bradshaw.

Author address: 

Bone Marrow Transplantation, University of Texas Health Science Center, San Antonio, TX, USA; Bone Marrow Transplantation, Texas Transplant Institute, San Antonio, TX, USA


Infection is the leading cause of morbidity and mortality among hematopoietic stem cell transplant (HSCT) recipients. Fungal infection is particularly a threat because of difficulty in both diagnosis and treatment. The frequency of fungal infection is largely dependent on the mode of transplantation and duration of neutropenia. While fluconazole prophylaxis in allogeneic and autologous BMT is well studied, a trial in autologous PBSCT is lacking. Methods: The Texas Stem Cell Transplant Consortium initiated a phase III randomized study to evaluate the efficacy of fluconazole for prophylaxis of invasive fungal infections (IFI) following autologous PBSCT with an initial planned enrollment of 150 patients. Patients were randomized to receive either no prophylaxis or fluconazole 400mg/day (or 12mg/kg if

abstract No: 


Full conference title: 

46th American Society for Haematology
    • ASH 46th (2004)